483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers

• Jeffrey Schlom,
• Ravi Madan,
• Seth Steinberg,
• James Gulley,
• Caroline Jochems,
• Renee Donahue,
• Sheri McMahon,
• Lisa Cordes,
• Julius Strauss,
• Fatima Karzai,
• Jason Redman,
• Charalampos Floudas,
• Clint Allen,
• Douglas Brough,
• Amy Lankford,
• Jenn Marte

Affiliations

Jeffrey Schlom

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Ravi Madan

Aff2 grid.48336.3a0000000419368075National Cancer Institute Bethesda MD USA

Seth Steinberg

Genitourinary Malignancies, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

James Gulley

NIH, Bethesda, MD, USA

Caroline Jochems

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Renee Donahue

NIH, Bethesda, MD, USA

Sheri McMahon

Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA

Lisa Cordes

Genitourinary Malignancies, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Julius Strauss

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Fatima Karzai

Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA

Jason Redman

Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA

Charalampos Floudas

Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA

Clint Allen

Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA

Douglas Brough

3Precigen, Inc., Germantown, MD, USA

Amy Lankford

3Precigen, Inc., Germantown, MD, USA

Jenn Marte

1NCI, NIH, Bethesda, MD, USA